Summary of Envista's Conference Call Industry Overview - The dental market is characterized as "soft but stable," with low single-digit growth observed over the past four quarters [2][3] - The consumables market has shown the most consistency, with low single-digit growth [3] - Orthodontics is experiencing low to mid-single-digit growth, with brackets and wires performing well [3] - The implant market is growing steadily, with a focus on digitization and equipment sales [4] - Diagnostics have been a negative low single-digit market but are showing signs of improvement [4] Company Performance - Envista has achieved approximately 5% growth year-to-date, with trends continuing positively into the fourth quarter [6][7] - December is a significant month for purchasing, and a strong finish to the year is anticipated [7] - The Spark business is expected to grow, with a consistent global aligner market performance [9][10] Product Innovations and Strategies - Envista has focused on providing a full solution to orthodontists, combining aligners with brackets and wires [10][11] - New product introductions, such as Spark On Demand and BiteSync, are aimed at enhancing treatment options and efficiency [12][13] - Continuous innovation is a key strategy, with a focus on both line extensions and new product launches [15] Financial Insights - The Spark business had a $45 million revenue headwind last year, with a significant portion expected to return this year [18][19] - A 20% year-over-year cost reduction in aligner production has been achieved through automation [21][22] - Envista's G&A expenses have decreased by 12% year-to-date, with expectations to maintain flat spending going forward [55] Market Dynamics - North America is recovering positively, while Europe continues to perform well [4][5] - China remains uncertain, with ongoing questions about market dynamics [5] - The diagnostics market is expected to recover modestly, driven by interest rate reductions and consumer confidence [47] R&D and Acquisitions - Envista invested $25 million in R&D for implants, focusing on commercial and clinical improvements [28] - Two acquisitions were made to enhance geographic penetration and product offerings in the implant space [33] Capital Deployment and Future Outlook - Envista aims for organic growth as the primary capital deployment strategy, with M&A opportunities also being a priority [62] - A share repurchase program of $250 million over two years has been approved [63] - The company anticipates a lower tax rate in 2026 due to improved profitability and the resolution of intercompany loans [58][59] Conclusion - Envista is positioned for continued growth through innovation, strategic acquisitions, and a focus on operational efficiency, with a positive outlook for 2026 and beyond [64][65]

Core Viewpoint - Envista Holdings Corporation reported strong financial results for Q3 2025, exceeding expectations in core growth, adjusted EBITDA, and adjusted EPS, with positive growth across all major business segments [2][6]. Financial Highlights - Q3 2025 sales reached $670 million, reflecting a core sales growth of 9.4% compared to Q3 2024 [6]. - The company reported a GAAP net loss of $30 million, attributed to a tax charge from restructuring intercompany loans, while adjusted net income was $54 million [3][6]. - Adjusted EBITDA for the quarter was $97 million, representing a 77% increase year-on-year, with an adjusted EBITDA margin of 14.5%, up 540 basis points from the previous year [6]. - For the first nine months of 2025, sales totaled $1,969 million, with a core sales growth of 5.0% compared to the same period in 2024 [6]. Cash Flow and Share Repurchases - Operating cash flow for Q3 2025 was $79 million, and free cash flow was $68 million, compared to $71 million and $63 million in Q3 2024, respectively [4]. - During the quarter, the company repurchased 2.1 million shares for approximately $41 million, with $108 million remaining under its stock repurchase program [4]. Outlook - Envista updated its full-year 2025 guidance, projecting core sales growth of approximately 4%, an adjusted EBITDA margin of around 14%, and adjusted diluted earnings per share between $1.10 and $1.15 [5][6]. Business Segment Performance - Specialty Products & Technologies segment sales were $431.5 million, up from $381.7 million in Q3 2024, while Equipment & Consumables segment sales increased to $238.4 million from $219.3 million [15]. - Operating profit for the Specialty Products & Technologies segment was $48.1 million, significantly higher than $12.3 million in the prior year [15].

Core Insights - Envista Holdings Corporation will report its financial results for the third quarter of 2025 on October 30, 2025, with a conference call scheduled for 2:00 PM PT [1] - The earnings press release and related materials will be available on the "Investors" section of Envista's website prior to the conference call [2] Company Overview - Envista is a global family of over 30 trusted dental brands, including Nobel Biocare, Ormco, DEXIS, and Kerr, focused on improving lives through dental care [3] - The company offers a comprehensive portfolio that includes dental implants, orthodontics, and digital imaging technologies, addressing a wide range of clinical needs for dental professionals [3] - Envista is recognized as one of the largest global dental products companies, holding significant market positions in attractive segments of the dental products industry [3]

Core Viewpoint - Envista Holdings Corporation will report its financial results for the second quarter of 2025 on July 31, 2025, with a conference call scheduled for 2:00 PM PT to discuss these results [1]. Company Overview - Envista is a global family of over 30 trusted dental brands, including Nobel Biocare, Ormco, DEXIS, and Kerr, focused on improving lives through dental care [4]. - The company offers a comprehensive portfolio that includes dental implants, orthodontics, and digital imaging technologies, addressing a wide range of clinical needs for dental professionals [4]. - Envista is recognized as one of the largest global dental products companies, holding significant market positions in attractive segments of the dental products industry [4]. Conference Call Details - The conference call will be accessible via a dial-in number, with a U.S. number of 1-800-836-8184 and an international number of +1 646-357-8785, starting a few minutes before the call [2]. - A replay of the webcast will be available shortly after the presentation concludes, and related materials will be posted on the "Investors" section of Envista's website [3].

Core Insights - Envista Holdings Corporation will participate in the Stifel 2025 Jaws & Paws Conference on May 28, 2025, from 1:50 – 2:20 pm ET, with a live audio webcast available on its website [1] Company Overview - Envista is a global family of over 30 trusted dental brands, including Nobel Biocare, Ormco, DEXIS, and Kerr, focused on improving lives through dental care [2] - The company offers a comprehensive portfolio that includes dental implants, orthodontics, and digital imaging technologies, addressing a wide range of clinical needs for dental professionals [2] - Envista is recognized as one of the largest global dental products companies, holding significant market positions in attractive segments of the dental products industry [2]